Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein

Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein

The respiratory syncytial virus (RSV) causes significant respiratory disease in young infants and the elderly. Immune prophylaxis in infants is currently limited to palivizumab, an anti-RSV fusion (F) protein monoclonal antibody (mAb). While anti-F protein mAbs neutralize RSV, they are unable to pre...

Full description

Bibliographic Details
Main Authors: Harrison C. Bergeron, Jackelyn Murray, Aakash Arora, Ana M. Nuñez Castrejon, Rebecca M. DuBois, Larry J. Anderson, Lawrence M. Kauvar, Ralph A. Tripp
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Viruses
Subjects:
RSV
G protein
F protein
mAb
3D3
2D10
Online Access:https://www.mdpi.com/1999-4915/15/5/1067

Internet

https://www.mdpi.com/1999-4915/15/5/1067

Similar Items